What’s behind Trump’s drug pricing proposal? This insight explores key policy tools, global scenarios, and long-term ...

OECD countries formally use QALYs in pricing and reimbursement decisions. See how HTA practices differ and where policies ...

Professor Graham Cookson responds to Chancellor's Spending Review announcement boosting NHS spend by 3%. Earlier today, UK ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

Pharmacogenomics (PGx) is the study of how genetic variation affects the efficacy and safety of medicines, enabling ...

Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually and impose economic costs exceeding $150 billion by 2050.

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...